I enlighet med de principer för inrättande av valberedning som tidigare beslutats på årsstämman 2024, har följande valberedning utsetts för Diagonal Bio AB (publ.) inför årsstämman den 20 maj, 2025.
Read moreDiagonal Bio today announces that the Nomination Committee has been appointed in preparation for the Annual General Meeting (AGM) on May 20, 2025.
Read moreDiagonal Bio AB (publ) (“Diagonal Bio” or “the Company”) will be participating in a partnered event with Svensk Galopp, at Jägersro on November 7, 2024. The Company’s diagnostic platform, LAMPlify®, will be introduced to a select group of invited trainers.
Read moreThe 24th of September 2024 is the last day of trading in warrants of series TO 1, which were issued in connection with Diagonal Bio AB’s (“Diagonal Bio” or the “Company”) preferential rights issue of units that was carried out earlier in 2024. The exercise period runs until the 26th of September 2024.
Read moreToday is the first day for the exercise of Diagonal Bio AB’s (“Diagonal Bio” or “the Company”) warrants of series TO 1 (“TO 1”) which were issued in connection with the preferential issue of units that the Company carried out earlier this year. The period lasts until June 26, 2024. Holders of TO 1 have the right to subscribe for one (1) new share in Diagonal Bio for each TO 1 at a price of SEK 0,05 per share. Through full utilisation of TO 1, the Company will receive approximately SEK 2,25 million before issue costs. An information document is available on the respective websites of Diagonal Bio (www.diagonalbio.com), Sedermera Corporate Finance AB (www.sedermera.se) and Nordic Issuing AB (www.nordic-issuing.se).
Read more
